|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit.
|
31405808 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with selective anti-PD1, anti-PD-L1 and/or anti-CTLA-4 monoclonal antibodies (mAbs) has been a revolution in the therapeutic scenario of several cancer types, with the highest clinical efficacy in melanoma and in lung cancer.
|
31079031 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
While inhibitors to CTLA-4 and the PD-1/PD-L1 axis are well-established for the clinical management of melanoma, many patients do not respond or develop resistance to these interventions.
|
30941125 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of PD-1 and CTLA-4 on Tregs might be a potential biomarker for the efficacy of immune checkpoint blockade in melanoma.
|
31145230 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results show that combining NDV plus radiotherapy with checkpoint inhibitors (PD1 or CTLA4 targeted mAbs) results in significantly better complete tumour regression rates with an abscopal effect in a murine model of melanoma than either single therapy combined with checkpoint inhibitors.
|
31676387 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, these results indicate the identification of a novel mechanism underlying melanoma progression in the present study and that CTLA-4-targeted therapy may benefit candidate CTLA-4-targeted therapy by improving the long-term outcome for patients with advanced stages of melanoma.
|
30344757 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma.
|
29606147 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review examines the mechanisms of action and the limitations of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies which are the two types of checkpoint inhibitors currently available to patients and further explores the future avenues of their use in melanoma and other cancers.
|
29644214 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
|
29704887 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings implicate autophagy suppression in resistance to CTLA-4 blockade in melanoma, suggesting exploitation of autophagy induction for potential therapeutic synergy with CTLA-4 inhibitors.
|
29656892 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
|
29769148 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
|
30063587 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data strongly support the assumption that mCTLA4 predicts response to both anti-PD-1 and anti-CTLA-4 targeted ICB in melanoma and provides paramount information for the selection of patients likely to respond to ICB.
|
29997292 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interventions were categorised into five groups: conventional chemotherapy (including single agent and polychemotherapy), biochemotherapy (combining chemotherapy with cytokines such as interleukin-2 and interferon-alpha), immune checkpoint inhibitors (such as anti-CTLA4 and anti-PD1 monoclonal antibodies), small-molecule targeted drugs used for melanomas with specific gene changes (such as BRAF inhibitors and MEK inhibitors), and other agents (such as anti-angiogenic drugs).
|
29405038 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma.
|
29403496 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-PD-1 + anti-CTLA-4 initiating sequences for BRAF wild-type melanoma are cost-effective versus anti-PD-1.
|
30175642 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RT-PCR was performed for 169 genes associated with inflammation, immunity, CTLA-4 pathway and melanoma.
|
30227886 |
2018 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Treatment options have expanded beyond high-dose interleukin 2 and adoptive T-cell therapy to include inhibitors of immune checkpoints programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and small molecular inhibitors of pathways activated in melanoma, in particular the mitogen-activated protein kinase (MAPK) pathway.
|
30154648 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed B cell changes in patients with melanoma following treatment with either anti-CTLA4 or anti-PD1, or in combination.
|
29309048 |
2018 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin's lymphoma.
|
29069302 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment of B16 melanoma‑bearing C57BL/6 mice with anti‑CTLA‑4 nanobody 16 (Nb16) delayed melanoma growth and prolonged the survival time of mice.
|
29207143 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antibodies targeting RANKL have recently been evaluated in combination with anti-CTLA4 in case reports of human melanoma and mouse models of cancer.
|
29872559 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunotherapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have showed significant therapeutic benefit in patients with clinically advanced solid malignancies, including melanoma.
|
29633300 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
|
29750753 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated whether NGR-TNF, a TNF derivative capable of targeting the tumor vasculature, and improving intratumor infiltration by activated CTLs, could sensitize tumors to ICB with antibodies specific for the PD-1 and CTLA-4 receptors.<b>Experimental Design:</b> Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice with autochthonous prostate cancer and C57BL/6 mice with orthotopic B16 melanoma were treated with NGR-TNF, adoptive T-cell therapy (ACT), and ICB, and monitored for immune surveillance and disease progression.<b>Results:</b> The combination of ACT, NGR-TNF, and ICB was the most effective in delaying disease progression, and in improving overall survival of mice bearing ICB-resistant prostate cancer or melanoma.
|
29490991 |
2018 |